First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Active, not recruiting · Phase 1 · NCT03401385
Conditions: Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $5.5M
- U.S. investigators named
- 12
- Sites paid
- 18
- Planned or actual enrollment
- 890
About the trial
- Sponsor
- Daiichi Sankyo Co., Ltd. (with Daiichi Sankyo, AstraZeneca)
- Tested
- Datopotamab Deruxtecan (Dato-DXd) (drug), Steroid Containing Mouthwash (drug), Non-Steroid Containing Mouthwash (other)
- Dates
- Started 2018-01-31; completion 2028-01-01
- Results posted
- Not yet
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a * Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites ar…
From ClinicalTrials.gov, last updated 2026-09-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $5.5M in research payments for this study in 2025 (277 payments).
Products named: Datroway
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Aaron Lisberg, MD Hematology & Oncology · Santa Monica, CA
- Manali A. Bhave, MD Medical Oncology · Chicago, IL
- Rebecca S. Heist, MD MPH Internal Medicine · Boston, MA
- Jacob M. Sands, MD Hematology & Oncology · Burlington, MA
- Jean H. Hoffman-censits, MD Medical Oncology · Baltimore, MD
- Deborah B. Doroshow, M.D., PH.D. Medical Oncology · New York, NY
- Shanu Modi, MD Medical Oncology · New York, NY
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Funda Meric, M.D. General Surgery · Houston, TX
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $1.5M
- Ut MD Anderson Cancer Center $1.4M
- Ronald Reagan UCLA Medical Center, CA $694,530
- Emory University Hospital, GA $363,276
- Sarah Cannon Research Institute $361,964
- Sarah Cannon Research Institute LLC $349,404
- Johns Hopkins University $192,885
- Icahn School of Medicine at Mount Sinai $152,290
- Mount Sinai Hospital, NY $101,539
- Next Oncology-San Antonio $84,745
- New Experimental Therapeutics of San Antonio Llc $83,995
- South Texas Accelerated Research Therapeutics Llc $44,743
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $34,365
- Virginia Cancer Specialists $30,038
- Virginia Cancer Specialists Fairfax $30,038
- Memorial Hospital for Cancer and All $26,056
- Memorial Sloan Kettering Cancer Center PAin Service $7,995
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.